Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Safety and tolerability of depot medroxyprogesterone acetate among HIV-infected women on antiretroviral therapy: ACTG A5093.

Watts DH, Park JG, Cohn SE, Yu S, Hitti J, Stek A, Clax PA, Muderspach L, Lertora JJ.

Contraception. 2008 Feb;77(2):84-90. doi: 10.1016/j.contraception.2007.10.002. Epub 2007 Dec 21.

2.

Depo-medroxyprogesterone in women on antiretroviral therapy: effective contraception and lack of clinically significant interactions.

Cohn SE, Park JG, Watts DH, Stek A, Hitti J, Clax PA, Yu S, Lertora JJ; ACTG A5093 Protocol Team.

Clin Pharmacol Ther. 2007 Feb;81(2):222-7. Epub 2006 Dec 27.

PMID:
17192768
3.

Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children.

Lapphra K, Vanprapar N, Chearskul S, Phongsamart W, Chearskul P, Prasitsuebsai W, Chokephaibulkit K.

Int J Infect Dis. 2008 Nov;12(6):e33-8. doi: 10.1016/j.ijid.2007.10.008. Epub 2008 Jun 24.

4.

Associations of hormonal contraceptive use with measures of HIV disease progression and antiretroviral therapy effectiveness.

Whiteman MK, Jeng G, Samarina A, Akatova N, Martirosyan M, Kissin DM, Curtis KM, Marchbanks PA, Hillis SD, Mandel MG, Jamieson DJ.

Contraception. 2016 Jan;93(1):17-24. doi: 10.1016/j.contraception.2015.07.003. Epub 2015 Jul 18.

5.

Pharmacokinetic interactions between depot medroxyprogesterone acetate and combination antiretroviral therapy.

Nanda K, Amaral E, Hays M, Viscola MA, Mehta N, Bahamondes L.

Fertil Steril. 2008 Oct;90(4):965-71. Epub 2007 Sep 19.

PMID:
17880953
6.

Effect of Depot Medoxyprogesterone Acetate on Immune Functions and Inflammatory Markers of HIV-Infected Women.

Weinberg A, Park JG, Bosch R, Cho A, Livingston E, Aweeka F, Cramer Y, Watts DH, Luque AE, Cohn SE.

J Acquir Immune Defic Syndr. 2016 Feb 1;71(2):137-45. doi: 10.1097/QAI.0000000000000850.

7.

Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression.

Gulick RM, Lalama CM, Ribaudo HJ, Shikuma CM, Schackman BR, Schouten J, Squires KE, Koletar SL, Pilcher CD, Reichman RC, Klingman KL, Kuritzkes DR.

AIDS. 2007 Apr 23;21(7):813-23.

PMID:
17415036
8.

Depot medroxyprogesterone acetate in combination with a twice-daily lopinavir-ritonavir-based regimen in HIV-infected women showed effective contraception and a lack of clinically significant interactions, with good safety and tolerability: results of the ACTG 5283 study.

Luque AE, Cohn SE, Park JG, Cramer Y, Weinberg A, Livingston E, Klingman KL, Aweeka F, Watts DH.

Antimicrob Agents Chemother. 2015 Apr;59(4):2094-101. doi: 10.1128/AAC.04701-14. Epub 2015 Jan 26.

9.

Comparison of two once-daily regimens with a regimen consisting of nelfinavir, didanosine, and stavudine in antiretroviral therapy-naïve adults: 48-week results from the Antiretroviral Regimen Evaluation Study (ARES).

Lowe SH, Wensing AM, Hassink EA, ten Kate RW, Richter C, Schreij G, Koopmans PP, Juttmann JR, van der Tweel I, Lange JM, Borleffs JC.

HIV Clin Trials. 2005 Sep-Oct;6(5):235-45.

PMID:
16306030
10.

Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.

Cruciani M, Mengoli C, Serpelloni G, Parisi SG, Malena M, Bosco O.

Cochrane Database Syst Rev. 2013 Jun 5;(6):CD008270. doi: 10.1002/14651858.CD008270.pub2. Review.

PMID:
23740608
11.

A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study.

Manosuthi W, Sungkanuparph S, Tantanathip P, Lueangniyomkul A, Mankatitham W, Prasithsirskul W, Burapatarawong S, Thongyen S, Likanonsakul S, Thawornwa U, Prommool V, Ruxrungtham K; N2R Study Team.

Clin Infect Dis. 2009 Jun 15;48(12):1752-9. doi: 10.1086/599114.

PMID:
19438397
12.

Physiologic doses of depot-medroxyprogesterone acetate do not increase acute plasma simian HIV viremia or mucosal virus shedding in pigtail macaques.

Radzio J, Hanley K, Mitchell J, Ellis S, Deyounks F, Jenkins LT, Hanson D, Heneine W, García-Lerma JG.

AIDS. 2014 Jun 19;28(10):1431-9. doi: 10.1097/QAD.0000000000000294.

PMID:
24759208
13.

Nelfinavir and nevirapine side effects during pregnancy.

Timmermans S, Tempelman C, Godfried MH, Nellen J, Dieleman J, Sprenger H, Schneider ME, de Wolf F, Boer K, van der Ende ME; Dutch HMF Study Group.

AIDS. 2005 May 20;19(8):795-9.

PMID:
15867493
14.

Hormonal contraception and HIV-1 disease progression among postpartum Kenyan women.

Richardson BA, Otieno PA, Mbori-Ngacha D, Overbaugh J, Farquhar C, John-Stewart GC.

AIDS. 2007 Mar 30;21(6):749-53.

15.

Preexposure prophylaxis is efficacious for HIV-1 prevention among women using depot medroxyprogesterone acetate for contraception.

Heffron R, Mugo N, Were E, Kiarie J, Bukusi EA, Mujugira A, Frenkel LM, Donnell D, Ronald A, Celum C, Baeten JM; Partners PrEP Study Team.

AIDS. 2014 Nov 28;28(18):2771-6. doi: 10.1097/QAD.0000000000000493.

16.

Hormonal contraceptive use and discontinuation among HIV-infected women in Uganda and Zimbabwe.

Bengtson A, Kwok C, Salata RA, Byamugisha J, Chipato T, Rwambuya S, Moyo P, Morrison CS.

J Acquir Immune Defic Syndr. 2013 Aug 1;63(4):506-13. doi: 10.1097/QAI.0b013e318293df9e.

17.

Depot medroxyprogesterone acetate versus an oral contraceptive combined with very-low-dose danazol for long-term treatment of pelvic pain associated with endometriosis.

Vercellini P, De Giorgi O, Oldani S, Cortesi I, Panazza S, Crosignani PG.

Am J Obstet Gynecol. 1996 Aug;175(2):396-401.

PMID:
8765259
18.

Physical findings and symptoms of depot medroxyprogesterone acetate use in adolescent females.

Matson SC, Henderson KA, McGrath GJ.

J Pediatr Adolesc Gynecol. 1997 Feb;10(1):18-23.

PMID:
9061630
19.

Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022.

Hitti J, Frenkel LM, Stek AM, Nachman SA, Baker D, Gonzalez-Garcia A, Provisor A, Thorpe EM, Paul ME, Foca M, Gandia J, Huang S, Wei LJ, Stevens LM, Watts DH, McNamara J; PACTG 1022 Study Team.

J Acquir Immune Defic Syndr. 2004 Jul 1;36(3):772-6.

PMID:
15213559
20.

Lack of effect from a previous single dose of nevirapine on virologic and immunologic responses after 6 months of antiretroviral regimens containing either efavirenz or lopinavir-ritonavir.

Dlamini JN, Hu Z, Somaroo H, Highbarger HC, Follmann DA, Dewar RL, Pau AK.

Pharmacotherapy. 2011 Feb;31(2):158-63. doi: 10.1592/phco.31.2.158.

Supplemental Content

Support Center